Luis Bujanda
Overview
Explore the profile of Luis Bujanda including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
391
Citations
8633
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Lopez-Pena A, Herreros-Villanueva M, Olga A, Hermoso-Duran S, Ajay G, Sarasqueta C, et al.
Dig Liver Dis
. 2025 Feb;
PMID: 39933973
Background: Pancreatic Cyst Lesions (PCLs) are frequently diagnosed in radiologic imaging tests and can be classified as benign, premalignant and malignant. Their correct stratification is essential and has significant implications...
2.
Olaizola P, Olaizola I, Fernandez de Ara M, Lapitz A, Val B, Izquierdo-Sanchez L, et al.
Hepatology
. 2025 Feb;
PMID: 39932259
Background And Rationale: Cholangiocarcinoma (CCA) includes a diverse group of biliary malignancies with poor prognosis. Alterations in post-translational modifications contribute to disrupted protein dynamics, cellular disturbances, and disease. This study...
3.
Casas Deza D, Alcedo J, Lafuente M, Lopez F, Perez-Aisa A, Pavoni M, et al.
Am J Gastroenterol
. 2025 Feb;
PMID: 39902822
Introduction: To evaluate the prescription patterns, effectiveness, and safety of adding probiotics to Helicobacter pylori eradication therapy, in Europe. Methods: International, prospective, noninterventional registry of the clinical practice of the...
4.
Baldan-Martin M, Azkargorta M, Lapitz A, Ortega Moreno L, Iloro I, Fernandez-Tome S, et al.
Int J Mol Sci
. 2025 Jan;
26(2.
PMID: 39859242
The proteomic analysis of serum extracellular vesicles (EVs) could be a useful tool for studying the pathophysiology of Crohn's disease (CD) and ulcerative colitis (UC), as well as for biomarker...
5.
Meyer A, Chan S, Touvier M, Julia C, Tjonneland A, Kyro C, et al.
Aliment Pharmacol Ther
. 2025 Jan;
61(6):1032-1042.
PMID: 39817326
Background: Association between dietary factors and the risk of developing inflammatory bowel disease (IBD) has been studied extensively. However, identification of deleterious dietary patterns merits further study. Aim: To investigate...
6.
Giordano A, Perez-Martinez I, Gisbert J, Ricart E, Martin-Arranz M, Mesonero F, et al.
Am J Gastroenterol
. 2025 Jan;
120(1):194-203.
PMID: 39745305
Introduction: Crohn's disease (CD) varies by location, potentially affecting therapy efficacy and surgery risk, although research on this topic is conflicting. This study aims to investigate the independent association between...
7.
Millastre J, Hermoso-Duran S, Solorzano M, Fraunhoffer N, Garcia-Rayado G, Vega S, et al.
Cancers (Basel)
. 2024 Dec;
16(23).
PMID: 39682210
Pancreatic cystic lesions (PCLs) are a heterogeneous group of lesions with increasing incidence, usually identified incidentally on imaging studies (multidetector computed tomography (MDCT), magnetic resonance imaging (MRI), or endoscopic ultrasound...
8.
da Fonseca L, Izquierdo-Sanchez L, Hashizume P, Carlino Y, Baca E, Zambrano C, et al.
Lancet Reg Health Am
. 2024 Dec;
40:100952.
PMID: 39655285
Background: Cholangiocarcinoma (CCA) represents a global health challenge, with rising incidence and mortality rates. This study aimed to elucidate the clinical course and practices of CCA in Latin America. Methods:...
9.
Llach J, Luzko I, Earl J, Barreto E, Rodriguez-Garrote M, Lleixa M, et al.
Cancers (Basel)
. 2024 Nov;
16(22).
PMID: 39594734
Background: Pancreatic ductal adenocarcinoma (PDAC) is associated with a significant percentage of germline pathogenic variants (GPVs). Unlike in the United States, routine universal genetic testing is not performed in Europe....
10.
Iturbe-Rey S, Maccali C, Arrese M, Aspichueta P, Oliveira C, Castro R, et al.
Atherosclerosis
. 2024 Nov;
400:119053.
PMID: 39581063
Metabolic dysfunction-associated steatotic liver disease (MASLD) encompasses a spectrum of liver lesions, ranging from simple steatosis to metabolic dysfunction-associated steatohepatitis (MASH), that may further progress to cirrhosis. MASLD is estimated...